|
DK2872491T3
(da)
|
2012-07-11 |
2021-08-09 |
Blueprint Medicines Corp |
Inhibitorer af fibroblastvækstfaktorreceptoren
|
|
PL2958916T3
(pl)
*
|
2013-02-21 |
2019-01-31 |
Pfizer Inc. |
Stałe postacie selektywnego inhibitora CDK4/6
|
|
BR112016008849B8
(pt)
|
2013-10-25 |
2022-09-06 |
Blueprint Medicines Corp |
Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
WO2016024249A1
(en)
*
|
2014-08-14 |
2016-02-18 |
Sun Pharmaceutical Industries Limited |
Crystalline forms of palbociclib
|
|
EP3186252A1
(en)
*
|
2014-08-28 |
2017-07-05 |
ratiopharm GmbH |
Method of producing palbociclib and pharmaceutical compositions comprising the same
|
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
CN104610254B
(zh)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
一种帕博赛布的低成本制备方法
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
|
CN106117199A
(zh)
*
|
2015-05-04 |
2016-11-16 |
江苏恒瑞医药股份有限公司 |
一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
|
|
HUE047477T2
(hu)
*
|
2015-06-04 |
2020-04-28 |
Pfizer |
Palbociclib szilárd dózisformái
|
|
CN106317053A
(zh)
*
|
2015-06-29 |
2017-01-11 |
北大方正集团有限公司 |
一种帕博昔布晶型a的制备方法
|
|
CN106397431A
(zh)
*
|
2015-07-28 |
2017-02-15 |
苏州国匡医药科技有限公司 |
一种抗肿瘤药物的新晶型及其制备方法和用途
|
|
CN105153149B
(zh)
*
|
2015-07-29 |
2017-09-19 |
江苏中邦制药有限公司 |
一种选择性激酶抑制剂Palbociclib的制备方法
|
|
US10526326B2
(en)
|
2015-08-05 |
2020-01-07 |
Ratiopharm Gmbh |
Crystalline form and acetic acid adducts of palbociclib
|
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
|
KR20250010141A
(ko)
|
2015-10-16 |
2025-01-20 |
애브비 인코포레이티드 |
(3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
|
|
CN106608876B
(zh)
*
|
2015-10-21 |
2018-06-19 |
新发药业有限公司 |
一种高纯度帕博西尼的制备方法
|
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
|
CN106632311B
(zh)
*
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
一种帕博西尼晶型a和晶型b的制备方法
|
|
CN106831759A
(zh)
*
|
2015-12-03 |
2017-06-13 |
上海星泰医药科技有限公司 |
帕布昔利布及其中间体的制备方法
|
|
CN105541832A
(zh)
*
|
2015-12-15 |
2016-05-04 |
南京艾德凯腾生物医药有限责任公司 |
一种羟乙基磺酸盐帕布昔利布的制备方法
|
|
WO2017115315A1
(en)
*
|
2015-12-30 |
2017-07-06 |
Dr. Reddy's Laboratories Limited |
Solid forms of palbociclib
|
|
CN105524059A
(zh)
*
|
2016-01-06 |
2016-04-27 |
北京修正创新药物研究院有限公司 |
一种帕波西比杂质的制备方法
|
|
GB201601329D0
(en)
|
2016-01-25 |
2016-03-09 |
Mohammad Mohammad A |
Inverse gas chromatography standard solutions, device and method
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
CN106336411B
(zh)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
|
|
WO2017197904A2
(zh)
*
|
2016-05-08 |
2017-11-23 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
CN105924439B
(zh)
*
|
2016-06-24 |
2017-11-24 |
石家庄海瑞药物科技有限公司 |
一种帕布昔利布的制备方法
|
|
CN106146494B
(zh)
*
|
2016-06-29 |
2018-02-06 |
重庆华邦制药有限公司 |
用于制备帕布昔利布a型晶的溶剂及制备方法
|
|
EP3481825A1
(en)
|
2016-07-07 |
2019-05-15 |
Plantex Ltd. |
Solid state forms of palbociclib dimesylate
|
|
CN106220627A
(zh)
*
|
2016-07-31 |
2016-12-14 |
合肥远志医药科技开发有限公司 |
一种高纯度帕布昔利布的工业化制备方法
|
|
CN106220626A
(zh)
*
|
2016-07-31 |
2016-12-14 |
合肥远志医药科技开发有限公司 |
一种帕布昔利布的多晶型及其制备方法
|
|
JP6563623B1
(ja)
|
2016-08-15 |
2019-08-21 |
ファイザー・インク |
ピリドピリミジノンｃｄｋ２／４／６阻害剤
|
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
|
WO2018065999A1
(en)
|
2016-10-07 |
2018-04-12 |
Mylan Laboratories Limited |
Novel polymorph of an intermediate for palbociclib synthesis
|
|
EP3804724B1
(en)
*
|
2016-10-20 |
2022-12-07 |
Pfizer Inc. |
Cdk inhibitors for treating pah
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
CN108017630B
(zh)
*
|
2016-10-31 |
2022-10-11 |
上海创诺制药有限公司 |
一种小比表面积帕博西尼游离碱的制备方法
|
|
US20190275049A1
(en)
|
2016-11-16 |
2019-09-12 |
Pfizer Inc. |
Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
|
|
CN108117550B
(zh)
*
|
2016-11-29 |
2020-08-14 |
上海医药工业研究院 |
吡啶并[2,3-d]嘧啶类化合物的制备方法
|
|
KR102513448B1
(ko)
|
2016-12-16 |
2023-03-23 |
씨스톤 파마슈티컬즈 |
Cdk4/6 억제제
|
|
CN110573183A
(zh)
*
|
2017-04-21 |
2019-12-13 |
上海方楠生物科技有限公司 |
一种帕博西林组合物及其制备方法
|
|
CN108864078B
(zh)
*
|
2017-05-10 |
2021-10-15 |
江苏豪森药业集团有限公司 |
帕博西尼晶型b的制备方法
|
|
CA3069523A1
(en)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
EA202090402A1
(ru)
|
2017-07-28 |
2020-05-19 |
Синтон Б.В. |
Фармацевтическая композиция, содержащая пальбоциклиб
|
|
KR102758037B1
(ko)
|
2017-08-18 |
2025-01-22 |
코테라 바이오사이언스 인코포레이티드 |
Tg02의 다형성 형태
|
|
CN111386272B
(zh)
|
2017-10-27 |
2023-01-06 |
费森尤斯卡比肿瘤学有限公司 |
一种改进的瑞博西尼及其盐的制备方法
|
|
CN109897034A
(zh)
*
|
2017-12-07 |
2019-06-18 |
南京卡文迪许生物工程技术有限公司 |
一种高纯度晶型a帕布昔利布及其制备方法和药物组合物
|
|
WO2019136451A1
(en)
|
2018-01-08 |
2019-07-11 |
G1 Therapeutics, Inc. |
G1t38 superior dosage regimes
|
|
CN108586452A
(zh)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
一种帕博西尼中间体的合成方法
|
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
|
|
CN108299422B
(zh)
*
|
2018-02-28 |
2019-10-25 |
杭州福斯特药业有限公司 |
一种帕泊昔利布中间体的制备方法
|
|
EP4309656A3
(en)
|
2018-05-14 |
2024-02-28 |
Pfizer Inc. |
Oral solution formulation
|
|
CN108558745A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种帕博西林中间体的合成方法
|
|
SI3802529T1
(sl)
|
2018-05-24 |
2024-03-29 |
Synthon B.V. |
Postopek za izdelavo palbocikliba
|
|
CN112292379B
(zh)
*
|
2018-06-13 |
2022-03-04 |
基石药业（苏州）有限公司 |
吡啶并吡啶酮衍生物的盐型及晶型
|
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
|
|
US11130757B2
(en)
|
2018-10-24 |
2021-09-28 |
Effector Therapeutics Inc. |
Crystalline forms of MNK inhibitors
|
|
CN109336886A
(zh)
*
|
2018-12-07 |
2019-02-15 |
重庆三圣实业股份有限公司 |
一种帕博西尼的制备方法及其产品
|
|
US20220127262A1
(en)
*
|
2019-01-17 |
2022-04-28 |
Pfizer Inc. |
Crystalline form of a cdk inhibitor
|
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
EP3976043A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
|
CN110256424A
(zh)
*
|
2019-07-03 |
2019-09-20 |
武汉工程大学 |
一种帕博西尼关键中间体v的合成方法
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
CN110551063A
(zh)
*
|
2019-10-17 |
2019-12-10 |
山东邹平大展新材料有限公司 |
一种合成5-(n-boc-哌嗪-1-基)吡啶-2-胺的方法
|
|
WO2021176349A1
(en)
|
2020-03-05 |
2021-09-10 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
|
EP4667055A3
(en)
|
2020-07-15 |
2026-02-25 |
Pfizer Inc. |
Kat6 inhibitor methods and combinations for cancer treatment
|
|
US20230321042A1
(en)
|
2020-07-20 |
2023-10-12 |
Pfizer Inc. |
Combination therapy
|
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
CN112274493A
(zh)
*
|
2020-11-18 |
2021-01-29 |
石药集团中奇制药技术（石家庄）有限公司 |
一种哌柏西利胶囊的制备方法
|
|
CN112457311B
(zh)
*
|
2020-12-04 |
2022-07-12 |
江苏豪森药业集团有限公司 |
一种含有氯溴吡咯嘧啶酮结构化合物的制备方法
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN112661753B
(zh)
*
|
2020-12-29 |
2022-06-03 |
山东铂源药业股份有限公司 |
一种帕布昔利布中间体的制备方法
|
|
CN112778303A
(zh)
*
|
2020-12-31 |
2021-05-11 |
武汉九州钰民医药科技有限公司 |
Cdk4/6激酶抑制剂shr6390的制备方法
|
|
CN112898299B
(zh)
*
|
2021-01-26 |
2021-11-26 |
山东铂源药业有限公司 |
一种帕布昔利布中间体的制备方法
|
|
EP4356398A4
(en)
|
2021-06-14 |
2025-04-16 |
Preh Holding, LLC |
CONNECTED BODY SURFACE CARE MODULE
|
|
EP4370126A4
(en)
|
2021-07-16 |
2025-05-28 |
Dana-Farber Cancer Institute, Inc. |
Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
|
|
CN113845520A
(zh)
*
|
2021-09-09 |
2021-12-28 |
安徽皓元药业有限公司 |
一种帕布昔利布乳清酸盐及其制备方法
|
|
CN113999227A
(zh)
*
|
2021-11-26 |
2022-02-01 |
常州大学 |
一种帕博西尼中间体的制备方法
|
|
AU2022408062B2
(en)
|
2021-12-10 |
2025-08-14 |
Eli Lilly And Company |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
|
|
US20250049802A1
(en)
|
2021-12-14 |
2025-02-13 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
CN114195784A
(zh)
*
|
2021-12-29 |
2022-03-18 |
斯坦德标准技术研究(湖北)有限公司 |
帕博西尼有关物质及其制备方法和应用
|
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
|
EP4302755B1
(en)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
|
CN119604288A
(zh)
|
2022-07-29 |
2025-03-11 |
辉瑞大药厂 |
用于治疗癌症的包含kat6抑制剂的给药方案
|
|
IL319242A
(en)
|
2022-08-31 |
2025-04-01 |
Arvinas Operations Inc |
Estrogen Receptor Blocker Dosage Regimen
|
|
CN120456897A
(zh)
|
2022-11-02 |
2025-08-08 |
佩特拉制药公司 |
用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
|
CN120981721A
(zh)
|
2023-03-30 |
2025-11-18 |
辉瑞大药厂 |
Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
US20250177414A1
(en)
|
2023-12-04 |
2025-06-05 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
|
WO2025202854A1
(en)
|
2024-03-27 |
2025-10-02 |
Pfizer Inc. |
Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
|
|
WO2026025013A2
(en)
|
2024-07-26 |
2026-01-29 |
Pfizer Inc. |
Combination therapy using cdk4 inhibitors for cancer treatments
|